Association between metabolic factors and chronic hepatitis B virus infection

World Journal of Gastroenterology

Volumn 20, Issue 23, 2014, Pages 7213-7216

  Chiang, Chien Hsieh ^a   Huang, Kuo Chin ^b  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Adiponectin; Diabetes; Hepatitis B surface antigen; Hepatitis B viral load; Hepatocellular carcinoma; Obesity

Indexed keywords

ADIPONECTIN; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN X; ADIPOQ PROTEIN, HUMAN; BIOLOGICAL MARKER;

ARTICLE; BODY MASS; CANCER INCIDENCE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL (TOPIC); DIABETES MELLITUS; DISEASE ASSOCIATION; GENE EXPRESSION; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HYPERTRIGLYCERIDEMIA; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER FUNCTION; METABOLIC SYNDROME X; METABOLISM; NONHUMAN; OBESITY; RISK FACTOR; SEROLOGY; STEATOSIS; VIRUS LOAD; VIRUS REPLICATION; ANIMAL; BLOOD; COMPLICATION; DYSLIPIDEMIAS; HEPATITIS B, CHRONIC; IMMUNOLOGY; LIVER TUMOR; PATHOGENICITY; VIROLOGY;

ADIPONECTIN; ANIMALS; BIOLOGICAL MARKERS; CARCINOMA, HEPATOCELLULAR; DIABETES MELLITUS; DYSLIPIDEMIAS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LIVER NEOPLASMS; OBESITY; RISK FACTORS; VIRAL LOAD; VIRUS REPLICATION;

EID: 84902663011     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i23.7213     Document Type: Article

References (30)

1. El-Serag HB. Hepatocellular carcinoma. N Engl J Med 2011; 365: 1118-1127 [PMID: 21992124 DOI: 10.1056/NEJMra1001683]
2. Liao SF, Yang HI, Lee MH, Chen CJ, Lee WC. Fifteen-year population attributable fractions and causal pies of risk factors for newly developed hepatocellular carcinomas in 11,801 men in Taiwan. PLoS One 2012; 7: e34779 [PMID: 22506050 DOI: 10.1371/journal.pone.0034779]
3. Wen CP, Lin J, Yang YC, Tsai MK, Tsao CK, Etzel C, Huang M, Hsu CY, Ye Y, Mishra L, Hawk E, Wu X. Hepatocellular carcinoma risk prediction model for the general population: the predictive power of transaminases. J Natl Cancer Inst 2012; 104: 1599-1611 [PMID: 23073549 DOI: 10.1093/jnci/djs372]
4. Liaw YF, Chu CM. Hepatitis B virus infection. Lancet 2009; 373: 582-592 [PMID: 19217993 DOI: 10.1016/S0140-6736(09)60207-5]
5. Huang KC. Obesity and its related diseases in Taiwan. Obes Rev 2008; 9 Suppl 1: 32-34 [PMID: 18307696 DOI: 10.1111/ j.1467-789X.2007.00435.x]
6. Yen SL, Chiu TY, Lin YC, Lee YC, Lee LT, Huang KC. Obesity and hepatitis B infection are associated with increased risk of metabolic syndrome in university freshmen. Int J Obes (Lond) 2008; 32: 474-480 [PMID: 17955029 DOI: 10.1038/ sj.ijo.0803753]
7. Jan CF, Chen CJ, Chiu YH, Chen LS, Wu HM, Huang CC, Yen MF, Chen TH. A population-based study investigating the association between metabolic syndrome and hepatitis B/C infection (Keelung Community-based Integrated Screening study No. 10). Int J Obes (Lond) 2006; 30: 794-799 [PMID: 16404404 DOI: 10.1038/sj.ijo.0803204]
8. Wang CC, Hsu CS, Liu CJ, Kao JH, Chen DS. Association of chronic hepatitis B virus infection with insulin resistance and hepatic steatosis. J Gastroenterol Hepatol 2008; 23: 779-782 [PMID: 18028349 DOI: 10.1111/j.1440-1746.2007.05216.x]
9. Wong VW, Wong GL, Chu WC, Chim AM, Ong A, Yeung DK, Yiu KK, Chu SH, Chan HY, Woo J, Chan FK, Chan HL. Hepatitis B virus infection and fatty liver in the general population. J Hepatol 2012; 56: 533-540 [PMID: 22027575 DOI: 10.1016/j.jhep.2011.09.013]
10. McManus DD, Lyass A, Ingelsson E, Massaro JM, Meigs JB, Aragam J, Benjamin EJ, Vasan RS. Relations of circulating resistin and adiponectin and cardiac structure and function: the Framingham Offspring Study. Obesity (Silver Spring) 2012; 20: 1882-1886 [PMID: 21350435 DOI: 10.1038/oby.2011.1032]
11. Chiang CH, Lai JS, Hung SH, Lee LT, Sheu JC, Huang KC. Serum adiponectin levels are associated with hepatitis B viral load in overweight to obese hepatitis B virus carriers. Obesity (Silver Spring) 2013; 21: 291-296 [PMID: 23404868 DOI: 10.1002/oby.20000]
12. Shlomai A, Shaul Y. The metabolic activator FOXO1 binds hepatitis B virus DNA and activates its transcription. Biochem Biophys Res Commun 2009; 381: 544-548 [PMID: 19233123 DOI: 10.1016/j.bbrc.2009.02.078]
13. Chiang CH, Lai JS, Sheu JC, Yen LL, Liu CJ, Huang KC. The risky body mass index ranges for significant hepatitis B viral load: A campus-based study. Obes Res Clin Pract 2012; 6: e1-e90 [PMID: 24331171 DOI: 10.1016/j.orcp.2011.04.005]
14. Wang SH, Yeh SH, Lin WH, Wang HY, Chen DS, Chen PJ. Identification of androgen response elements in the enhancer I of hepatitis B virus: a mechanism for sex disparity in chronic hepatitis B. Hepatology 2009; 50: 1392-1402 [PMID: 19670412 DOI: 10.1002/hep.23163]
15. Chiang CH, Yang HI, Jen CL, Lu SN, Wang LY, You SL, Su J, Iloeje UH, Chen CJ. Association between obesity, hypertriglyceridemia and low hepatitis B viral load. Int J Obes (Lond) 2013; 37: 410-415 [PMID: 22531094 DOI: 10.1038/ijo.2012.63]
16. Wong VW, Wong GL, Yu J, Choi PC, Chan AW, Chan HY, Chu ES, Cheng AS, Chim AM, Chan FK, Sung JJ, Chan HL. Interaction of adipokines and hepatitis B virus on histological liver injury in the Chinese. Am J Gastroenterol 2010; 105: 132-138 [PMID: 19809411 DOI: 10.1038/ajg.2009.560]
17. Yoon S, Jung J, Kim T, Park S, Chwae YJ, Shin HJ, Kim K. Adiponectin, a downstream target gene of peroxisome proliferator-activated receptor γ, controls hepatitis B virus replication. Virology 2011; 409: 290-298 [PMID: 21059469 DOI: 10.1016/j.virol.2010.10.024]
18. Chen CL, Yang HI, Yang WS, Liu CJ, Chen PJ, You SL, Wang LY, Sun CA, Lu SN, Chen DS, Chen CJ. Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection: a follow-up study in Taiwan. Gastroenterology 2008; 135: 111-121 [PMID: 18505690 DOI: 10.1053/ j.gastro.2008.03.073]
19. Inoue M, Kurahashi N, Iwasaki M, Tanaka Y, Mizokami M, Noda M, Tsugane S. Metabolic factors and subsequent risk of hepatocellular carcinoma by hepatitis virus infection status: a large-scale population-based cohort study of Japanese men and women (JPHC Study Cohort II). Cancer Causes Control 2009; 20: 741-750 [PMID: 19115074 DOI: 10.1007/ s10552-008-9287-6]
20. Lai MS, Hsieh MS, Chiu YH, Chen TH. Type 2 diabetes and hepatocellular carcinoma: A cohort study in high prevalence area of hepatitis virus infection. Hepatology 2006; 43: 1295-1302 [PMID: 16729295 DOI: 10.1002/hep.21208]
21. Davila JA, Morgan RO, Shaib Y, McGlynn KA, El-Serag HB. Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study. Gut 2005; 54: 533-539 [PMID: 15753540 DOI: 10.1136/ gut.2004.052167]
22. Brower V. Illuminating the diabetes-cancer link. J Natl Cancer Inst 2012; 104: 1048-1050 [PMID: 22781433 DOI: 10.1093/ jnci/djs322]
23. Chen CJ, Yang HI, Iloeje UH. Hepatitis B virus DNA levels and outcomes in chronic hepatitis B. Hepatology 2009; 49: S72-S84 [PMID: 19399801 DOI: 10.1002/hep.22884]
24. Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, Huang GT, Iloeje UH. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295: 65-73 [PMID: 16391218 DOI: 10.1001/jama.295.1.65]
25. Strohmaier S, Edlinger M, Manjer J, Stocks T, Bjørge T, Borena W, Häggström C, Engeland A, Nagel G, Almquist M, Selmer R, Tretli S, Concin H, Hallmans G, Jonsson H, Stattin P, Ulmer H. Total serum cholesterol and cancer incidence in the Metabolic syndrome and Cancer Project (Me-Can). PLoS One 2013; 8: e54242 [PMID: 23372693 DOI: 10.1371/journal. pone.0054242]
26. Tsan YT, Lee CH, Ho WC, Lin MH, Wang JD, Chen PC. Statins and the risk of hepatocellular carcinoma in patients with hepatitis C virus infection. J Clin Oncol 2013; 31: 1514-1521 [PMID: 23509319 DOI: 10.1200/jco.2012.44.6831]
27. Tsan YT, Lee CH, Wang JD, Chen PC. Statins and the risk of hepatocellular carcinoma in patients with hepatitis B virus infection. J Clin Oncol 2012; 30: 623-630 [PMID: 22271485 DOI: 10.1200/jco.2011.36.0917]
28. Nseir W, Mograbi J, Ghali M. Lipid-lowering agents in nonalcoholic fatty liver disease and steatohepatitis: human studies. Dig Dis Sci 2012; 57: 1773-1781 [PMID: 22419057 DOI: 10.1007/s10620-012-2118-3]
29. Kang SK, Chung TW, Lee JY, Lee YC, Morton RE, Kim CH. The hepatitis B virus X protein inhibits secretion of apolipoprotein B by enhancing the expression of N-acetylglucosaminyltransferase III. J Biol Chem 2004; 279: 28106-28112 [PMID: 15123606 DOI: 10.1074/jbc.M403176200]
30. Yamasaki D, Kawabe N, Nakamura H, Tachibana K, Ishimoto K, Tanaka T, Aburatani H, Sakai J, Hamakubo T, Kodama T, Doi T. Fenofibrate suppresses growth of the human hepatocellular carcinoma cell via PPARα-independent mechanisms. Eur J Cell Biol 2011; 90: 657-664 [PMID: 21514001 DOI: 10.1016/j.ejcb.2011.02.005]